Free Trial

Artiva Biotherapeutics (ARTV) News Today

Artiva Biotherapeutics logo
$10.72
+0.58 (+5.72%)
(As of 11/1/2024 ET)
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (NASDAQ:ARTV) Shares Down 5.4% - Time to Sell?
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4% - Time to Sell?
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (NASDAQ:ARTV) Rating Reiterated by Wedbush
Wedbush reaffirmed an "outperform" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday.
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Wedbush
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics, Inc.'s (NASDAQ:ARTV) Quiet Period Will End on August 28th
Artiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) quiet period is set to expire on Wednesday, August 28th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. During Artiva Biotherapeutics' quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Artiva Biotherapeutics shares get Overweight rating
Artiva Biotherapeutics, Inc. stock logo
Analysts Set Expectations for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV)
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Research analysts at Wedbush issued their Q2 2024 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report issued on Tuesday, August 13th. Wedbush analyst D. Nierengarten expects that the company will earn ($1.5
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. stock logo
Jefferies Financial Group Begins Coverage on Artiva Biotherapeutics (NASDAQ:ARTV)
Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research report on Tuesday. They set a "buy" rating and a $21.00 price target for the company.
Artiva Biotherapeutics Inc ARTV
Artiva Biotherapeutics Inc (ARTV)
Get Artiva Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.

625,000% Gain (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

ARTV Media Mentions By Week

ARTV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARTV
News Sentiment

-1.00

0.38

Average
Medical
News Sentiment

ARTV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARTV Articles
This Week

1

1

ARTV Articles
Average Week

Get Artiva Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ARTV) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners